QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

INDV

QT79Indivior Pharmaceuticals Inc
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA
Latest market price
38.30
+0.37+0.98%
OverviewShort InterestFilings
INDVQT79Indivior Pharmaceuticals Inc·NASDAQ
OverviewShort InterestFilings
38.30+0.98%
TA
Loading chart...
Screen all →
TAK+1.36%$15.63HLN+1.01%$8.96TEVA-3.32%$31.48VTRS-2.29%$15.37ELAN+3.55%$24.22RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86
Snapshot
Index-P/E18.94EPS (ttm)
1.98
Insider Own0.88%
Shs Outstand121.00M
Perf Week0.45%
Market Cap4.73BForward P/E9.65EPS next Y3.97Insider Trans0.53%Shs Float-Perf Month3.54%
Enterprise Value5.07BPEG0.01EPS next Q0.88Inst Own-Short Float-Perf Quarter25.57%
Income249.88MP/S3.67EPS this Y86.77%Inst Trans-Short Ratio-Perf Half Y8.25%
Sales1.29BP/B-EPS next Y7.30%ROA20.97%Short Interest-Perf YTD6.74%
Book/sh-1.19P/C-EPS next 5Y5.89%ROE-142.01%52W High41.00 -6.59%Perf Year178.14%
Cash/sh1.45P/FCF-EPS past 3/5Y-ROIC85.68%52W Low13.45 184.76%Perf 3Y-
Dividend Est.-EV/EBITDA14.39Sales past 3/5Y11.20% 13.88%Gross Margin83.11%Volatility1.80% 2.47%Perf 5Y-
Dividend TTM-EV/Sales3.92EPS Y/Y TTM19966.67%Oper. Margin33.31%ATR (14)1.25Perf 10Y-
Dividend Ex-DateJun 16, 2016Quick Ratio0.66Sales Y/Y TTM8.67%Profit Margin19.44%RSI (14)57.95Recom2.00
Dividend Gr. 3/5Y-Current Ratio0.86EPS Q/Q134.15%SMA202.87%Beta0.52Target Price48.00
Payout0.00%Debt/Eq-3.53Sales Q/Q19.17%SMA505.80%Rel Volume1.90Prev Close37.93
Employees1,030LT Debt/Eq-3.18EarningsJul 30SMA20019.57%Avg Volume1.95MPrice38.30
IPO DateDec 29, 2014Option/ShortYes / YesEPS/Sales Surpr.50.00% 16.12%Net Debt/EBITDA0.95Volume3,706,369Change0.98%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-18-26InitiatedBarclaysOverweight$46
Jan-20-26ReiteratedNorthland Securities$40 → $50
Jan-12-26ReiteratedH.C. Wainwright$35 → $48
Dec-03-25ReiteratedMorgan Stanley$28 → $36
Oct-31-25ReiteratedCraig-HallumBuy$34 → $41
Oct-31-25ReiteratedNorthland Securities$30 → $40
Oct-30-25ReiteratedH.C. Wainwright$28 → $35
Aug-27-25ReiteratedCraig-HallumBuy$20 → $34
Mar-06-25ReiteratedPiper SandlerOverweight$15 → $13
Oct-11-24ReiteratedPiper SandlerOverweight$22 → $15
Latest News
Jun-18-26
Jun-18-2608:49AM
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,2911,2391,188
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A218246231
Gross Profit1,073993957
Selling, General and Administrative Excl. Other570634618
Research and Development7497107
Other Operating Expense-1-3200
Operating Income43026532
Interest Expense404541
Unusual Expense
———
Non-Operating Income (Expense)95-19-23
Net Income Before Taxes29523914
Income Taxes442911
Consolidated Net Income2512102
Net Income From Continuing Operations2512103
Net Income2512102
EPS (Recurring)2.011.680.02
EPS (Basic, Before Extraordinaries)2.011.680.02
EPS (Diluted)1.981.640.02
EBITDA35230484
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio19.3421.88—
Price To Sales Ratio3.713.62—
Gross Margin83.1180.1580.56
Operating Margin33.3121.392.69
Net Margin19.4416.950.17
Shares Outstanding125125132
Market Capitalization4,7884,485—
Operating Lease Expense
———
Insider Trading Volume
$42.39$37.26$32.13$26.99$21.86● Close Price0.00M0.52M1.03M1.55M2.06MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Heidbreder ChristianChief Scientific OfficerJun 11 '26Sale38.0618,586707,383227,923Jun 12 12:00 AM
Preblick RyanChief Financial OfficerJun 08 '26Sale37.7036,0001,357,200284,751Jun 10 12:00 AM
Preblick RyanChief Financial OfficerMar 14 '26Option Exercise0.0012,6040323,594Mar 17 12:00 AM
Ryan BarbaraDirectorMar 13 '26Buy31.0982495,724Mar 13 12:00 AM
Ryan BarbaraDirectorMar 09 '26Buy32.56311,0095,716Mar 11 12:00 AM
Kingsley Stuart ADirectorMar 06 '26Buy31.8694029,9535,582Mar 11 12:00 AM
Anderson Woodrow DChief Accounting OfficerMar 03 '26Option Exercise0.0054,231029,657Mar 05 12:00 AM
Preblick RyanChief Financial OfficerMar 03 '26Option Exercise0.00200,4590317,292Mar 05 12:00 AM
Burris Jeffrey WChief Legal OfficerMar 03 '26Option Exercise0.00184,1930107,550Mar 05 12:00 AM
Heidbreder ChristianChief Scientific OfficerMar 03 '26Option Exercise0.00234,1090292,306Mar 05 12:00 AM
Ryan BarbaraDirectorJan 05 '26Buy35.3977527,4291,963Jan 07 12:00 AM
Humphreys KeithDirectorJan 05 '26Buy35.3977527,4295,802Jan 07 12:00 AM
NINIVAGGI DANIEL ADirectorJan 05 '26Buy35.3977527,42916,923Jan 07 12:00 AM
Stejbach MarkDirectorJan 05 '26Buy35.3977527,42916,847Jan 07 12:00 AM
Wheadon David E.DirectorJan 05 '26Buy35.391,77162,68014,395Jan 07 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR